Bayer's stock has been the subject of various market observations and speculations recently. The company's future outlook through
2030 hints at significant momentum, although it currently may lag behind other medical stocks. A shift in narrative is anticipated with
OCEANIC-STROKE's Asundexian data impacting Bayer's position on
innovation and risk. Both Morgan Stanley and Bank of America have raised Bayer's stock price target to
EUR 55 citing litigation views and Supreme Court case optimism respectively. Additionally, Bayer's shares have surged due to revived fortunes for blood thinner, government backing for Supreme Court review in Roundup Case and positive expectations for prostate-cancer drug developed alongside a partner. Furthermore, the experimental blood thinner has reportedly cut stroke recurrence risk by 26%. However, Bayer's 88% surge in
2025 is still queried as to whether it signifies a real turnaround following restructuring and ongoing litigation. Despite some concerns of inflated earnings due to soccer transfers, Bayer shares continue to thrive with a significant positive response to its Q3 earnings from crop science business and upcoming stroke trial results.
BAYER Stocks News Analytics from Tue, 13 May 2025 07:00:00 GMT to Thu, 12 Feb 2026 13:08:39 GMT -
